History of stroke or transient ischemic attack
Subjects with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 6 months
History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months of first dose of AMG 757
History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 3 months.
History of stroke or transient ischemic attack within the previous 6 months
History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 6 months prior to Day 1
History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 6 months prior to initiation of study treatment
History of stroke or transient ischemic attack within 6 months prior to registration
History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 3 months Infection requiring intravenous antibiotics within 1 week of study enrollment (day 1)
History of stroke or transient ischemic attack within 6 months prior to day 1
History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months of enrollment.
History of stroke or transient ischemic attack within 6 months of the randomization
History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 6 months prior to Day 1
Symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within 30 days), ischemic stroke, or amaurosis fugax (monocular visual ischemic symptoms or blindness).
Cerebrovascular disease manifested as prior stroke at any time or transient ischemic attack (TIA) in the 12 months prior to initiation of therapy
History of stroke or transient ischemic attack within 6 months prior to registration
History of stroke or transient ischemic attack within 3 months prior to cycle 1, day 1
History or presence of serious hemorrhage , hemoptysis or hematemesis within 3 months or a thromboembolic event (including Deep Vein Thrombosis (DVT), stroke and/or transient ischemic attack) within 6 months; Patients with squamous Non Small Cell Lung Cancer (NSCLC) should be excluded.
Cerebrovascular event (transient ischemic attack, stroke or CNS bleeding) within the last 12 months.
History of stroke or transient ischemic attack within six months
History of stroke or transient ischemic attack within 6 months prior to study enrollment
History of stroke or transient ischemic attack within 6 months prior to day 1
History of transient ischemic attack (TIA) or stroke within 6 months of study entry
Stroke within 6 months of screening, or transient ischaemic attack (TIA) within 3 months of screening
215 History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months of first dose of AMG 562.
History of transient ischemic attack within the previous 6 months
History of stroke or transient ischemic attack =< 6 months prior to registration
History of stroke or transient ischemic attack within six months
History of stroke or transient ischemic attack within 6 months prior to Day1
History of stroke or transient ischemic attack within 6 months prior to study enrollment
History of stroke or transient ischemic attacks within 6 months prior to study enrolment.
Patients are excluded if they have a history of stroke or transient ischemic attack within 6 months prior to randomization
History of stroke or transient ischemic attack within 6 months prior to cycle 1, day 1
History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months prior to registration
History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months
History of stroke or transient ischemic attack within 6 months
History of stroke or transient ischemic attack within 6 months prior to beginning treatment.
History of stroke or transient ischemic attack, or other arterial thrombosis =< 12 months prior to randomization
Participants may not have had a history of a stroke or transient ischemic attack within six months
History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months
Patients must have not have a history of hemorrhagic or ischemic stroke, including transient ischemic attacks and other central nervous system bleeding in the preceding 6 months that were not related to glioma surgery
Stroke or transient ischemic attack
Myocardial infarction and transient ischemic attack or stroke within 6 months prior to enrollment
History of a stroke or transient ischemic attack within 6 months
-  History of stroke or transient ischemic attack within 6 months prior to Day 1.
History of significant cerebrovascular disease (i.e. stroke or transient ischemic attack [TIA]) in the past 6 months or ongoing event with active symptoms or sequelae
History of stroke or transient ischemic attack within 6 months prior to day 1
Prior history of stroke or transient ischemic attack within 6 months prior to day -3
History of stroke or transient ischemic attack
History of stroke or transient ischemic attack within six months
History of stroke or transient ischemic attack (TIA) within 6 months prior to Cycle 1, Day 1
History of stroke or transient ischemic attack within 6 months prior to Day 1
Past history of stroke or transient ischemic attack requiring medical therapy
Symptomatic peripheral vascular disease, stroke or transient ischemic attack within 6 months
History of stroke or transient ischemic attack within 3 months prior to registration
History of stroke or transient ischemic attack within 6 months prior to beginning treatment.
History of stroke or transient ischemic attack within 6 months prior to study enrollment
History of stroke or transient ischemic attack within 6 months prior to day 1
History of stroke or transient ischemic attack within 3 months of first study dose
No history of stroke or transient ischemic attack
History of stroke, reversible ischemic neurological defect or transient ischemic attack within 6 months prior to Day 1
History of progressive promyelocytic leukemia (PML), known history of pancreatitis, active grade 3 or higher viral, bacterial or fungal infection =< 2 weeks prior to registration and documented history of cerebrovascular event (stroke or transient ischemic attack [TIA]) =< 6 months prior to registration
Stroke or transient ischemic attack within 6 months of screening
History of stroke or transient ischemic attack in the preceding 6 months
History of stroke/transient ischemic attack